Verified intelligence · Expert-reviewed from public records, platform data, primary sources, and private research beyond AI search.

INFRALife sciencesGLOBAL

AI infrastructure for life sciences data and labs

Life-sciences AI infrastructure depends on which notebook methods, sample records, instrument files, omics runs and automation logs can cross into AI use while preserving source ownership, permissions, reviewer action and validation evidence.

The colophon

Landscape reviewed: 2026-06-01
Latest revision: 2026-06-01
Kinetics: Lab AI infrastructure is now judged by how much notebook, sample, raw-file, omics and automation work can cross into AI use without losing lineage, rights or validation state. Validation evidence can change before lab-system renewal when intended use, supplier releases, omics run provenance or consent inheritance shifts.
Known unknowns: An independent like-for-like benchmark or longitudinal telemetry set is missing for approval rate, validation effort, lineage repair, reviewer burden, failed runs, cost and accepted-output accuracy across the same lab-informatics, scientific-data-cloud, omics and automation workflow.

Contents

Executive summary
Decision frame
Data lineage
ELN, LIMS and SDMS
Omics workflows
Lab automation
GxP validation
IP boundaries
Private evals
Implementation economics
Operating risks
Recommended next steps
Known unknowns
Vendor and stack directory
Source ledger
Glossary

▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒Executive summary

The scarce control is lab-work survivorship. A notebook entry, sample record, raw file, omics run, automation log or partner dataset should cross into AI use only when sample identity, method version, run ID, consent or IP label, reviewer action and validation state remain attached.

Notebook expansion, LIMS modernization, data lakes, model workspaces and lab automation solve different control problems. Electronic notebooks protect methods and signatures; LIMS protects samples, tests and chain of custody; scientific data clouds normalize instrument files; omics platforms preserve run identity and consent; automation adds command authority. The infrastructure job is to join those proofs without hiding the formal record.

Regulated and quality-system workflows need provenance, permission, accountable review and a revalidation trigger; FDA CSA frames software assurance around intended use and risk-based evidence ¹. Controlled-access genomic reuse also needs source rights and permission boundaries before AI use ²⁶.

The commercial decision is where to own the conversion logic that carries lab evidence into AI use. External platforms fit record lanes when supplier evidence lowers GxP work; proprietary science needs owned rules for assay interpretation, protocol variants, negative results, compound context, consent boundaries and partner-data terms.

The first useful metric is the share of lab work that reaches AI without losing provenance, permission or validation state.

Vendor and standards sources show workflow shape; accepted-output economics require private measurement in the buyer's own lab.

Lab-work approval decision

Question	Answer	Action
What should be approved first?	The lab-work unit by data class and workflow: sample, method, raw file, run, automation command, reviewer action and rights label.	Classify notebook, LIMS, SDMS, omics, instrument, automation and partner-data evidence separately.
Where should AI work begin?	With read-only evidence search over objects whose source, lineage, rights and reviewer rules are already clear.	Pilot search, summarization and analysis before write-back, batch calculation or lab action.
What is the denominator?	The share of lab work that reaches AI with lineage, rights and validation state intact.	Use the metric to separate external record platforms, owned conversion logic and model deployment timing.
Where should the platform boundary sit?	Validated systems of record where supplier evidence reduces validation burden; scientific-data layers where they improve raw-file and run reuse.	Use external platforms for regulated records and commodity controls; own the lineage, rights and conversion logic specific to the science.
What should be blocked?	Unlabelled proprietary data, consent-limited genomics, GxP records without audit trails and automation commands without release authority.	Block AI use until source, rights, lineage, owner and retest trigger are explicit.

The policy matters when it raises the share of reusable lab work and blocks data that has lost source, rights or validation state.

Decision tree for lab AI

Start with the lab-work unit. If the sample, method, run, rights and reviewer trail are incomplete, keep AI read-only or outside the workflow.

Is the workflow GxP, clinical-trial, GLP, GMP or submission-supporting?
Yes
Use a validated workflow with audit trail, e-signature, intended-use evidence and change control.
No
Continue to proprietary and consent boundaries.
Next: Q2 rights
Does the data include proprietary protocols, compound structures, sequences, negative results or partner material?
Yes
Use a controlled scientific workspace or private model channel with explicit retention and use limits.
No
Use approved research-data paths and continue to lineage.
Next: Q3 lineage
Can the workflow trace sample, method, instrument, run, transformation, reviewer and output?
Yes
Pilot accepted-output tests and reviewer workflow.
No
Fix lineage before adding AI use or automation authority.
Will the AI action touch a robot, instrument, batch record, regulated submission or external partner?
Yes
Require human approval, simulation evidence, command logs, rollback and incident playbooks.
No
Use read-only or analyst-in-the-loop workflows until the risk tier changes.

The decision object is approved lab evidence for research, development, quality and data reuse. Life-sciences AI infrastructure has five evidence objects: system record, scientific data product, workflow run, automation command and approved AI context. The record layer is ELN, LIMS, LES, SDMS, chromatography data systems and quality systems. The data-product layer normalises instrument files, assay outputs and metadata. The workflow layer handles omics and analysis runs. The automation layer executes or coordinates physical work. The model layer reasons over approved context.

One enterprise platform can cover several layers, but the evidence questions stay separate. Model use can be acceptable for public literature and blocked for proprietary assay design. A cloud omics workflow can be acceptable for research analysis ²¹ and still insufficient for a regulated submission without validation evidence ²³.

Model serving, licence, GPU and retrieval economics matter only after the lab evidence object decides whether the model should see the data at all.

The lab evidence converter preserves experiment records, omics consent labels, raw instrument files, method execution and GxP validation state as data moves into AI use.

Evidence conversion by lab lane

Lane	Source of truth	AI use	Approval gate
ELN and experiment design	Notebook record, protocol, materials, attachments and signatures.	Search, protocol drafting, prior-experiment comparison and controlled write-back.	Notebook role, e-signature need, audit trail and GxP intended use.
LIMS, LES and quality control	Sample, inventory, method execution, specification, result and review state.	Exception triage, method assistance, release-support analysis and deviation drafting.	Part 11 or Annex 11 controls, validation packet, reviewer queue and SOP fit.
Instrument and SDMS layer	Raw files, parser output, metadata, calibration and source anchor.	Data harmonisation, table extraction, trend analysis and cross-instrument search.	Raw-data preservation, parser validation, chain of custody and ontology fit.
Omics workflow platform	Read set, reference, workflow, run UUID, container, variant or annotation store.	Pipeline troubleshooting, cohort analysis, variant annotation and research summarization.	Consent label, controlled-access rule, workflow version, run provenance and compute policy.
Lab automation and cloud lab	Command script, instrument state, run log, sample movement and result file.	Design-of-experiment support, protocol simulation, scheduling and constrained command generation.	Simulation, physical safety, method lock, human approval and incident response.
LLM and model-serving route	Approved AI context, retrieval source, gateway log and output review.	Reasoning, summarization, extraction, workflow guidance and agent orchestration.	Approve licence, hosting, retrieval, routing and economics against the lab data boundary.

Price each workflow by reviewer-accepted evidence: traceable experiment summary, reproducible omics run, controlled write-back, validated calculation or safe automation command.

Vendor and standards sources show workflow shape. Buyer-specific accepted-output economics require private measurement.

Accepted outputs set the cost denominator

Route	Accepted output	Hidden cost	Board rule
Validated notebook, LIMS and SDMS systems	Accepted record update, result review or controlled write-back.	Configuration, validation, training, reviewer queues and reapproval.	Use external systems when supplier evidence reduces validation burden.
Scientific data foundation	Reusable dataset with raw-file anchor, metadata and lineage.	Parser validation, ontology work, metadata repair and source reconciliation.	Use when instruments, formats and sites make custom harmonisation brittle.
Omics workflow platform	Reproducible run or accepted annotation with versioned inputs.	Workflow maintenance, consent labels, run provenance and reruns.	Use when reproducibility and access inheritance matter more than generic storage.
Automation or cloud lab	Accepted experiment or command sequence, including failed-run evidence.	Simulation, physical safety, deviation handling and human release.	Pilot in research before granting regulated command authority.
Model and retrieval layer	Accepted scientific answer or action under approved data terms.	Context curation, access filters, prompt logs, review time and fallback routes.	Self-host only when data boundary or output economics justify the burden.

After the lab data boundary and accepted-output denominator are fixed, the next dependency is deployment architecture: licence, hosting, retrieval, serving engine, GPU cost and recovery route.

Related report

Deployment options for open-source LLM models

Deployment architecture for model licence, open-weight hosting, serving engines, retrieval control, GPU cost and accepted-output economics.

Terms used in this report

Term	Plain meaning
Route	The approved path from work to accepted output: source set, data boundary, model or vendor channel, tools, reviewer, evidence record and reapproval trigger.
API	Application programming interface: a governed software connection used by an app or workflow to call a model or service.
LLM	Large language model: a model trained to read and generate text-like tokens.
Token	A chunk of text used for billing, context windows and rate limits. It is usually smaller than a word, not a page count.

Definitions are reader aids, not separate evidence claims.

MCP PREVIEW INVENTORY

What the locked report contains

Schema endpoints

Sample object: /api/v1/reports/RPT_01KSHN11BYPHQYZYV4EJK3NYY8/sample
Inventory object: /api/v1/reports/RPT_01KSHN11BYPHQYZYV4EJK3NYY8/inventory
Schema contract: /api/v1/reports/RPT_01KSHN11BYPHQYZYV4EJK3NYY8/schema

Coverage fields

Category: INFRA
Sector: Life sciences
Region: GLOBAL
Topics: life sciences AI, ELN, LIMS, SDMS, omics, bioinformatics workflows, lab automation, cloud labs, GxP validation, computer software assurance, 21 CFR Part 11, EU Annex 11, data lineage, scientific data standards, IP boundaries

Schema contract

Contract: colophon.report_document v2026-05-28
Payload schemas: document, summary, sample, inventory, full_report
Required top-level fields: title, subtitle, abstract, category, sector, region, topics, sources, evidence, claims, colophon, body
Integrity rules: evidence.sourceId must reference sources[].id claim.evidenceIds[] must reference evidence[].id evidence.claimIds[] must reference claims[].id section and block evidence references must resolve colophon.kinetics.speed must match the momentum band for the business impact x momentum model

Data-point inventory

vendor_or_actor_ledger: entity names; product categories; source references; confidence notes
buyer_decision_fields: pricing signals; deployment constraints; risk flags; monitoring fields
evidence_index: source class; access date; claim linkage; verification status

Section inventory

1. Executive summaryPreview
decision-ready conclusions; major findings; confidence caveats
2. Decision framePreview
selection criteria; tradeoff map; recommended buyer actions
3. Data lineageLocked
structured findings; supporting evidence; buyer-use fields
4. ELN, LIMS and SDMSLocked
structured findings; supporting evidence; buyer-use fields
5. Omics workflowsLocked
structured findings; supporting evidence; buyer-use fields
6. Lab automationLocked
structured findings; supporting evidence; buyer-use fields
7. GxP validationLocked
structured findings; supporting evidence; buyer-use fields
8. IP boundariesLocked
structured findings; supporting evidence; buyer-use fields
9. Private evalsLocked
structured findings; supporting evidence; buyer-use fields
10. Implementation economicsLocked
structured findings; supporting evidence; buyer-use fields
11. Operating risksLocked
structured findings; supporting evidence; buyer-use fields
12. Recommended next stepsLocked
structured findings; supporting evidence; buyer-use fields
13. Known unknownsLocked
structured findings; supporting evidence; buyer-use fields
14. Vendor and stack directoryLocked
normalized entity rows; source ledger; evidence-to-claim mapping
15. Source ledgerLocked
normalized entity rows; source ledger; evidence-to-claim mapping
16. GlossaryPreview
structured findings; supporting evidence; buyer-use fields

Relevance signals

Confidence score: 0.85
Source classes: fda_guidance, regulation, regulatory_guidance, industry_standard, glp_guidance, vendor_docs, product_docs, lab_data_standard, lab_automation_standard, lab_automation_docs, case_study, research_paper, omics_cloud_docs, omics_platform_docs, workflow_platform_docs, data_access_policy, data_access_standard, data_standard, data_lineage_standard
Known unknowns: An independent like-for-like benchmark or longitudinal telemetry set is missing for approval rate, validation effort, lineage repair, reviewer burden, failed runs, cost and accepted-output accuracy across the same lab-informatics, scientific-data-cloud, omics and automation workflow.
Watch signals:

Locked continuation

Purchase or subscribe to unlock the full findings, evidence ledger, and buyer-ready recommendations.